The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Disclosed herein is a method for treating an osteoarthritis in a subject in need thereof. The method mainly includes administering to the subject an effective amount of isolated mitochondria. According to some embodiments of the present disclosure, the isolated mitochondria are administered to the subject in need in the amount of about 1 mg/kg to about 100 mg/kg.

Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways. Linking the myoblast transfer technology development from DMD, cardiomyopathy, and Type-II diabetes, the myoblast transfer demonstrably mediates its effect through transfer of the normal myoblast nuclei that supply the complete human genome, in addition to just replenishing the missing gene(s) or the aberrant gene(s). The replacement genes then transcribe to produce the necessary proteins or factors for genetic repair. A variety of uses of this technology are described, including that for disease treatment, disease prevention, drug discovery, and selection of superior cells and clones for therapy

Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways. Linking the myoblast transfer technology development from DMD, cardiomyopathy, and Type-II diabetes, the myoblast transfer demonstrably mediates its effect through transfer of the normal myoblast nuclei that supply the complete human genome, in addition to just replenishing the missing gene(s) or the aberrant gene(s). The replacement genes then transcribe to produce the necessary proteins or factors for genetic repair. A variety of uses of this technology are described, including that for disease treatment, disease prevention, drug discovery, and selection of superior cells and clones for therapy

Compositions of matter comprising decellularized omentum are disclosed. The compositions may be scaffolds, hydrogels or hydrogel precursor compositions. Methods of generating the compositions are disclosed as well as uses thereof.

Compositions of matter comprising decellularized omentum are disclosed. The compositions may be scaffolds, hydrogels or hydrogel precursor compositions. Methods of generating the compositions are disclosed as well as uses thereof.

The present invention provides a method for culturing vascular smooth muscle cells, which includes culturing vascular smooth muscle cells in suspension in a medium composition comprising a structure capable of culturing cells or tissues by suspending them. In addition, the present invention provides a method for suppressing proliferation of vascular smooth muscle cells, which includes culturing vascular smooth muscle cells in suspension in the medium composition. Furthermore, the present invention provides a method for preserving vascular smooth muscle cells, which includes suspending vascular smooth muscle cells in the medium composition. The structure contains, for example, deacylated gellan gum.

The present invention provides a method for culturing vascular smooth muscle cells, which includes culturing vascular smooth muscle cells in suspension in a medium composition comprising a structure capable of culturing cells or tissues by suspending them. In addition, the present invention provides a method for suppressing proliferation of vascular smooth muscle cells, which includes culturing vascular smooth muscle cells in suspension in the medium composition. Furthermore, the present invention provides a method for preserving vascular smooth muscle cells, which includes suspending vascular smooth muscle cells in the medium composition. The structure contains, for example, deacylated gellan gum.

The invention relates to in vitro methods for isolating, or producing selected populations of human epicardial cells derived from human pluripotent stem cells; defined mixtures of said cells, and therapeutic uses thereof. Said population comprises epicardial cells with or without the potential to differentiate into cardiac fibroblasts, or a mixture thereof.